Full Library
Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases
Resource type
Journal Article
Author/contributor
- Benamu, Esther (Author)
Title
Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases
Abstract
The recognition of the role of complement and Janus kinase (JAK)–dependent cytokines
in the pathogenesis of inflammatory and immune-mediated disorders has revolutionized
the treatment of a myriad of rheumatological and inflammatory diseases. C5 inhibitors
and Janus kinase inhibitors have emerged as attractive therapeutic options. Because
of the blockage of immune pathways, these targeted therapies carry an increased risk
of infection. This article reviews the mechanism of action and the approved and off-label
indications of the agents with most clinical experience within this drug classes.
It discusses the associated risks of infection, proposing screening, prevention, and
risk mitigation strategies.
Publication
Infectious Disease Clinics
Date
2020/06/01
Volume
34
Issue
2
Pages
271-310
Journal Abbr
Infectious Disease Clinics
Accessed
9/1/21, 3:44 PM
ISSN
0891-5520, 1557-9824
Language
English
Library Catalog
Extra
Publisher: Elsevier
PMID: 32444011
Citation
Benamu, E. (2020). Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infectious Disease Clinics, 34(2), 271–310. https://doi.org/10.1016/j.idc.2020.02.014
HEME-ONC AND CELLULAR THERAPIES
Link to this record